tirzepatide weight regain study for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Trajectory of weight regain after

Plaintiffs argue that had they been informed of the risks, they might have made different decisions regarding their treatment options

Orlistat does nothing to stop you from wanting to eat

doi:10.1016/j.atherosclerosis.2011.12.039

Aib: -aminoisobutyric acid ApoB: apolipoprotein B CKD: chronic kidney disease FDA: Food and Drug Administration GI: gastrointestinal GLP-1 RA: glucagon-like peptide-1 receptor agonist HCC: hepatocellular carcinoma LDL-C: low-density lipoprotein cholesterol MASH: metabolic dysfunction-associated steatohepatitis MRI-PDFF: magnetic resonance imaging-proton density fat fraction NAFLD: nonalcoholic fatty liver disease NASH: nonalcoholic steatohepatitis T2DM: type 2 diabetes mellitus THR-: thyroid hormone receptor- This comparative perspective provides a summary of current evidence and should not be misconstrued as medical advice